Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.08 EUR
134.98 M EUR
652.07 M EUR
93.28 M
About Corcept Therapeutics Incorporated
Sector
Industry
CEO
Joseph K. Belanoff
Website
Headquarters
Redwood City
Founded
1998
ISIN
US2183521028
FIGI
BBG000BF8LN3
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange Corcept Therapeutics Incorporated. stocks are traded under the ticker HTD.
We've gathered analysts' opinions on Corcept Therapeutics Incorporated. future price: according to them, HTD price has a max estimate of 123.83 EUR and a min estimate of 103.34 EUR. Watch HTD chart and read a more detailed Corcept Therapeutics Incorporated. stock forecast: see what analysts think of Corcept Therapeutics Incorporated. and suggest that you do with its stocks.
Yes, you can track Corcept Therapeutics Incorporated. financials in yearly and quarterly reports right on TradingView.
Corcept Therapeutics Incorporated. is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
HTD earnings for the last quarter are 0.25 EUR per share, whereas the estimation was 0.16 EUR resulting in a 54.67% surprise. The estimated earnings for the next quarter are 0.14 EUR per share. See more details about Corcept Therapeutics Incorporated. earnings.
Corcept Therapeutics Incorporated. revenue for the last quarter amounts to 165.05 M EUR, despite the estimated figure of 169.27 M EUR. In the next quarter, revenue is expected to reach 191.92 M EUR.
HTD net income for the last quarter is 29.38 M EUR, while the quarter before that showed 18.75 M EUR of net income which accounts for 56.68% change. Track more Corcept Therapeutics Incorporated. financial stats to get the full picture.
No, HTD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 28, 2025, the company has 500 employees. See our rating of the largest employees — is Corcept Therapeutics Incorporated. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Corcept Therapeutics Incorporated. EBITDA is 88.15 M EUR, and current EBITDA margin is 20.49%. See more stats in Corcept Therapeutics Incorporated. financial statements.
Like other stocks, HTD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Corcept Therapeutics Incorporated. stock right from TradingView charts — choose your broker and connect to your account.